American College of Cardiology (ACC)

The American College of Cardiology (ACC) is the primary U.S. medical society representing the interests of all cardiology subspecialities. The ACC is very active in setting guidelines for cardiac care, lobbying for supportive government policy and reimbursements, clinician education, managing several key cardiovascular registries and advocating for the transformation of cardiovascular care to improve heart health.

CMS proposal includes cardiologist pay bump—cuts to high-value services still a concern
The 2026 MPFS proposed rule includes higher conversion factors across the board. However, some cardiology groups remain concerned about a series of reimbursement reductions for high-value cardiology services.
Medical malpractice lawsuits are rare in sports cardiology—but they can cost providers millions
When doctors are accused of mishandling the heart health of a young athlete, it occasionally ends up being settled in a courtroom.
EHR-driven PCI risk assessments could make a world of difference
Researchers with Mayo Clinic have shown that EHR-driven risk assessments could go a long way toward improving care for PCI patients.
At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving
Has the success of TAVR and other interventional techniques had a negative impact on surgical valve innovation? Two surgeons shared their concerns in a new commentary.
Polymer heart valve, the first of its kind to gain commercial approval, linked to positive 1-year data
The new-look mitral valve is built using LifePolymer, a proprietary material that does not include any animal tissue. Both the frame and its leaflets are robotically generated to match each patient’s anatomy.

CMS proposal includes cardiologist pay bump—cuts to high-value services still a concern

The 2026 MPFS proposed rule includes higher conversion factors across the board. However, some cardiology groups remain concerned about a series of reimbursement reductions for high-value cardiology services.

Medical malpractice lawsuits are rare in sports cardiology—but they can cost providers millions

When doctors are accused of mishandling the heart health of a young athlete, it occasionally ends up being settled in a courtroom.

heart data research doctor cardiologist AI

EHR-driven PCI risk assessments could make a world of difference

Researchers with Mayo Clinic have shown that EHR-driven risk assessments could go a long way toward improving care for PCI patients.

At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving

Has the success of TAVR and other interventional techniques had a negative impact on surgical valve innovation? Two surgeons shared their concerns in a new commentary.

Polymer heart valve, the first of its kind to gain commercial approval, linked to positive 1-year data

The new-look mitral valve is built using LifePolymer, a proprietary material that does not include any animal tissue. Both the frame and its leaflets are robotically generated to match each patient’s anatomy.

The first Black American College of Cardiology (ACC) president Kim Allan Williams, Sr., MD, MACC, MASNC, FAHA, FESC, chair, department of medicine, University of Louisville School of Medicine, explains the impact of Trump administration restrictions on diversity equity and inclusion (DEI) on healthcare programs and clinical trials that address women, minority and low-income patients.

How anti-DEI healthcare policies are impacting patient care

All over the United States, countless research projects designed to improve outcomes have lost funding or been shut down. Even screening efforts targeting patients in impoverished communities have been impacted by these policies.

The Evoque transcatheter tricuspid valve replacement (TTVR) system for tricuspid regurgitation from Edwards Lifesciences

TTVR with Evoque system linked to positive real-world outcomes after 30 days

According to early real-world data, the FDA-approved Evoque TTVR device is associated with positive outcomes when used to treat severe tricuspid regurgitation.

EnCompass F2 device from Nevada-based EnCompass Technologies

A closer look at world’s first TAVR patient treated with new cerebral embolic protection device

The device covers three vessels at once and can be deployed through the patient's TAVR access site. Researchers shared their first-in-human experience in JACC: Case Reports.